Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Commentary|Articles|May 8, 2026
FAQ: Identifying Undiagnosed Hypercortisolism and Subsequent Treatment
Author(s)Gillian McGovern, Editor
Fact checked by: Jennifer Goldman, PharmD, RPh, CDCES, BC-ADM, FCCP, Ron Panarotti
Pharmacists are vital in identifying at-risk patients, supporting diagnostic testing, optimizing therapy, and monitoring medication adjustments.
Advertisement
Advertisement
This FAQ was fact-checked by Jennifer Goldman, PharmD, CDCES, BC‑ADM, FCCP.
Related to this article
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Advertisement
Advertisement